Review and update on drugs related to the development of osteonecrosis of the jaw
NAGIOS: RODERIC FUNCIONANDO

Review and update on drugs related to the development of osteonecrosis of the jaw

DSpace Repository

Review and update on drugs related to the development of osteonecrosis of the jaw

Show simple item record

dc.contributor.author Eguía Del Valle, Asier es
dc.contributor.author Bagán Debón, Leticia es
dc.contributor.author Cardona Tortajada, Francisco es
dc.date.accessioned 2021-01-14T10:11:37Z
dc.date.available 2021-01-14T10:11:37Z
dc.date.issued 2020 es
dc.identifier.uri https://hdl.handle.net/10550/77080
dc.description.abstract Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of certain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or aflibercept. Very recently, new medications have also been associated with osteonecrosis of the jaw (ONJ). The objectives were to update the list of medications associated with ONJ, to analyze the fundamental aspects of this list and to describe the level of evidence available. A narrative bibliographic review was made, using the PubMed-MedLine, DOAJ and SCIELO databases. Additional information was obtained through the online Medication Information Centre of the Spanish Agency of Medicines and Medical Devices (AEMPS ? CIMA), the websites of the US Food & Drugs Administration (Drugs@FDA) and the European Medicines Agency (EMA). The latest drugs identified as potential facilitators of this pathology include a number of anti-VEGF based antiangiogenic drugs and anti-TKI and different types of immunomodulators. Neither the level of evidence in this association nor the risk are equal for all these drugs. On the other hand, over the coming years, new drugs will be marketed with similar action mechanisms to those that are recognized as having this adverse effect. No effective therapy is currently known for the treatment of ONJ. Therefore, in order to prevent new cases of MRONJ, it is essential for all oral healthcare professionals to be fully up-to-date with the etiopathogenic aspects of this pathology and to be aware of those drugs considered to be a risk. es
dc.source Eguía Del Valle, Asier ; Bagán Debón, Leticia ; Cardona Tortajada, Francisco. Review and update on drugs related to the development of osteonecrosis of the jaw. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 25 1 2020: 10- es
dc.title Review and update on drugs related to the development of osteonecrosis of the jaw es
dc.type info:eu-repo/semantics/article en
dc.type info:eu-repo/semantics/publishedVersion en
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi 10.4317/medoral.23191 es

View       (421.6Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics